GlobeNewswire

Global Blockchain Services Firm WACHSMAN Recruits Key Executives from Jefferies and J.P. Morgan to Lead New Strategy Division

Dela

Wachsman amplifies service offerings beyond public relations and events management with first major agency expansion

 

NEW YORK, NY, June 13, 2018 (GLOBE NEWSWIRE) -- Wachsman, one of the world's leading blockchain professional services firms, has hired senior bankers from investment banks Jefferies and J.P. Morgan to lead a new blockchain strategy and advisory division. Formerly Senior Vice President, Technology Investment Banking Group at Jefferies, Michael Chang joins Wachsman as Managing Director Strategy and will lead the firm's new Strategic Advisory Group in New York. Chang will be supported by Associate Director Franklin Bi, former Vice President and Blockchain Strategy Lead for J.P. Morgan's Blockchain Center of Excellence. Wachsman's Strategic Advisory Group will provide blockchain consulting and advisory services to Wachsman's existing clients as well as publicly-traded corporations and privately-held companies globally.

CEO David Wachsman said: "Today is a landmark occasion for our rapidly growing company. We have exceeded our clients' expectations with world-class public relations support and many of them have asked us to do more for them. With the experience and expertise that Michael and Franklin share, we now have the talent to offer a wider range of services. Subject matter expertise in this world-changing technology is extremely valuable, so we're proud to have attracted some of the brightest minds in blockchain to lead our new Strategic Advisory Group."

During his tenure at Jefferies, Chang founded and led the firm's blockchain coverage effort where he developed and executed blockchain strategies for clients ranging from large corporations, to institutional investors, to emerging blockchain companies. Prior to Jefferies, Chang was a Director in the Mergers and Acquisitions Group at Bank of America Merrill Lynch and Vice President at Citigroup, where he advised on over $40 Billion in M&A and capital raising transactions. Michael holds a Master of Business Administration from Cornell University, where he was a Roy H. Park Leadership Fellow.

Wachsman Managing Director Strategy, Michael Chang said: "I'm honored to bring my experience advising some of the world's largest companies to Wachsman in the fastest growing industry of our generation, blockchain. We can all see the growth trajectory for blockchain and digital assets, but organizations seldom have the experience to guide companies through how to best employ the technology. The Strategic Advisory Group will advise companies on how to accelerate their strategic objectives utilizing blockchain technology to better reach and serve their customers in new and exciting ways."

Franklin Bi spent four years at J.P. Morgan leading business strategy and use case prioritization for blockchain initiatives across wholesale banking, custody and fund services, and capital markets. Bi was responsible for driving J.P. Morgan's initial assessment of the impact of blockchain technology in 2015, co-authored the J.P. Morgan report, "Unlocking Economic Advantage with Blockchain," and played a key role in initiatives such as J.P. Morgan's Quorum project, crypto-asset strategy, and consortia engagement. Bi graduated from The Wharton School at the University of Pennsylvania with a Bachelor of Science in Economics.

Wachsman was founded by David Wachsman in December 2015 and has grown to employ 90 staff worldwide, with a client portfolio of some of the largest and indispensable companies and projects in the blockchain ecosystem, including CoinDesk, eToro, Dash, tZERO, Steemit, Bitfinex, Crypto Valley Association, and Lisk.


###

 

About Wachsman:

Wachsman is a leading professional services firm for the blockchain industry. Originally founded as a Public Relations agency in December 2015, Wachsman has expanded its service offerings to include Event Management and Strategic Advisory. The Strategic Advisory Group will be led by former Senior Vice President of Jefferies' Blockchain Coverage Group, Michael Chang, and supported by former Vice President and Blockchain Strategy Lead at J.P. Morgan's Blockchain Center of Excellence, Franklin Bi. Since the company's founding, Wachsman has grown to 90 people with offices in New York City and Dublin. The firm has represented more than 100 blockchain-focused companies, including some of the largest brands in the industry. David Wachsman is the Founder and CEO of Wachsman. Emma Walker is the Managing Director of Wachsman Europe.



Amanda Woodward
Wachsman 
917-900-2738
amanda@wachsman.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Wachsman via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum